Cargando…
Huntington’s Disease Drug Development: A Phase 3 Pipeline Analysis
Huntington’s Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities. The disorder is a result of a trinucleotide repeat expansion mutation that is inherited in a...
Autores principales: | Van de Roovaart, Hannah J., Nguyen, Nguyen, Veenstra, Timothy D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674993/ https://www.ncbi.nlm.nih.gov/pubmed/38004378 http://dx.doi.org/10.3390/ph16111513 |
Ejemplares similares
-
Targets for future clinical trials in Huntington's disease: What's in the pipeline?
por: Wild, Edward J, et al.
Publicado: (2014) -
Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017) -
Alzheimer's disease drug development pipeline: 2022
por: Cummings, Jeffrey, et al.
Publicado: (2022) -
Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023) -
Neuroprotective Effects of Psychotropic Drugs in Huntington’s Disease
por: Lauterbach, Edward C.
Publicado: (2013)